Wolverine Trading
BCRX icon

Wolverine Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wolverine Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,609
Closed -$80.6K – 4778
2024
Q2 		$65.6K Buy
+10,609
New +$58.5K ﹤0.01% 4174
2024
Q1 		– Sell
-16,364
Closed -$92K – 4501
2023
Q4 		$98K Buy
+16,364
New +$94.8K ﹤0.01% 4112
2023
Q2 		– Sell
-15,825
Closed -$127K – 4244
2023
Q1 		$133K Buy
+15,825
New +$152K ﹤0.01% 3587
2022
Q2 		– Sell
-27,389
Closed -$283K – 4506
2022
Q1 		$450K Buy
+27,389
New +$439K ﹤0.01% 3367
2021
Q4 		– Sell
-32,855
Closed -$472K – 5835
2021
Q3 		$472K Sell
32,855
-33,945
-51% -$535K ﹤0.01% 4020
2021
Q2 		$1.03M Sell
66,800
-29,102
-30% -$395K ﹤0.01% 2748
2021
Q1 		$958K Buy
95,902
+33,022
+53% +$340K ﹤0.01% 2812
2020
Q4 		$472K Buy
62,880
+26,238
+72% +$135K ﹤0.01% 3235
2020
Q3 		$141K Sell
36,642
-1,373
-4% -$5.88K ﹤0.01% 3998
2020
Q2 		$189K Buy
38,015
+512
+1% +$2.04K ﹤0.01% 3863
2020
Q1 		$75K Buy
37,503
+19,552
+109% +$53.8K ﹤0.01% 4124
2019
Q4 		$58K Buy
+17,951
New +$45.2K ﹤0.01% 4423
2019
Q3 		– Sell
-47,732
Closed -$148K – 4313
2019
Q2 		$181K Buy
+47,732
New +$287K ﹤0.01% 3768
2019
Q1 		– Sell
-27,701
Closed -$218K – 4523
2018
Q4 		$218K Buy
27,701
+17,075
+161% +$133K ﹤0.01% 3602
2018
Q3 		$81K Buy
+10,626
New +$71.4K ﹤0.01% 4602
2017
Q4 		– Sell
-10,480
Closed -$55K – 4896
2017
Q3 		$55K Buy
+10,480
New +$53.7K ﹤0.01% 4213
2017
Q2 		– Sell
-33,605
Closed -$280K – 4264
2017
Q1 		$280K Buy
33,605
+4,264
+15% +$29.7K ﹤0.01% 3106
2016
Q4 		$186K Sell
29,341
-37,284
-56% -$194K ﹤0.01% 3806
2016
Q3 		$296K Buy
+66,625
New +$266K ﹤0.01% 3252

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's BCRX Position: Q3 2024 in Review

Wolverine Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 10,609 shares — an estimated $80.6K sold.

Wolverine Trading first reported a position in BCRX in Q3 2016 and held it in 19 quarters. The position peaked at $1.03M in Q2 2021. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • Wolverine Trading reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Wolverine Trading sold 10,609 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $80.6K.
  • Wolverine Trading first reported a position in BioCryst Pharmaceuticals in Q3 2016 and held it in 19 quarters.
  • Wolverine Trading's BioCryst Pharmaceuticals position peaked at $1.03M in Q2 2021.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.